Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: CT-P13

Health Canada Approves CT-P13 SC for RA; Plus Tofacitinib May Increase Cardiac & Cancer Risks

Michele B. Kaufman, PharmD, BCGP  |  March 5, 2021

In Canada, a subcutaneous formulation of CT-P13, which is biosimilar to infliximab, was approved to treat rheumatoid arthritis.

Filed under:Biologics/DMARDsConditions Tagged with:CanadaCT-P13Drug SafetyFDAinfliximabRheumatoid Arthritis (RA)Tofacitinib

Subcutaneous CT-P13 Injection Evaluated for Safety & Efficacy of in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  July 22, 2019

Results from a one-year study suggest subcutaneous CT-P13, which is biosimilar to infliximab, is as safe and effective for RA patients as intravenous (IV) CT-P13 and IV infliximab…

Filed under:Biologics/DMARDsDrug UpdatesEULAR/OtherMeeting Reports Tagged with:CT-P13EULARinfliximabRheumatoid Arthritis (RA)

Mucosal Healing Seen with Infliximab Biosimilar CT-P13 in Ulcerative Colitis

Reuters Staff  |  May 3, 2016

NEW YORK (Reuters Health)—About two-thirds of patients with ulcerative colitis (UC) had mucosal healing by the end of induction treatment with the infliximab biosimilar CT-P13, according to results of the first prospective study to evaluate this. CT-P13 is the first biosimilar monoclonal antibody of reference infliximab (Remicade) approved in Europe and several other countries where…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsinfliximabinfliximab-dyybmonoclonal antibodyulcerative colitis

Medicalwriters/Science Source

Biosimilars Are Slowly Climbing Toward Acceptance in Rheumatology

Bryn Nelson, PhD  |  June 15, 2020

As useful stand-ins for biologics targeting a range of inflammatory diseases, biosimilars have made significant inroads across Europe as less expensive alternatives. Denmark, for example, realized a cost savings of 64% after instituting a mandatory national switch from the originator infliximab to its biosimilar counterpart. In the U.S., however, a considerably smaller fraction of rheumatologists…

Filed under:Biologics/DMARDsResearch Rheum Tagged with:Arthritis & Rheumatologydrug costsinfliximab

EU Approves Remsima SC, a Biosimilar to Infliximab

Michele B. Kaufman, PharmD, BCGP  |  January 2, 2020

Subcutaneous CT-P13 (Remsima SC), biosimilar to infliximab, will soon be available in the E.U. to treat adults with rheumatoid arthritis…

Filed under:Biologics/DMARDsDrug Updates

IBD Patients Who Switch from Infliximab to Biosimilar See Mixed Results

Will Boggs MD  |  April 22, 2019

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) can safely switch from infliximab to the biosimilar CT-P13, though they may face a higher risk of clinical relapse, researchers from Spain report. Recent studies have demonstrated the effectiveness and safety of infliximab biosimilars in patients with IBD, but there are limited data about the effectiveness…

Filed under:Biologics/DMARDsDrug Updates Tagged with:biosimilar CT-P13inflammatory bowel disease (IBD)infliximabinfliximab biosimilar

Can Integrated Care Lead to Better Outcomes?

Can Integrated Care Lead to Better Outcomes?

Shikha Mittoo, MD, MHS, FRCPC  |  December 17, 2018

A typical patient with a rheumatic disease needs a multifaceted treatment approach to address comorbidities, minimize disability, promote quality of life and improve survival. To achieve these outcomes, rheumatology research has evolved from examining a single treatment to studying the best treatment approaches. Examples of these strategy trials include how to best combine pharmaceutical therapies,…

Filed under:Conditions Tagged with:Association of Rheumatology Professionals (ARP)Integrated Careinterdisciplinarymultidisciplinary care

Study Says 1 Biosimilar Switch Is OK; Jury Still Out on Multiple Switches

Thomas R. Collins  |  August 17, 2018

AMSTERDAM—As more biosimilar drugs for rheumatic diseases make their way to market, evidence is growing that switching from the originator drug to a biosimilar tends to be effective, while the questions of switching back and forth, and switching multiple times using several different biosimilars, remain to be answered, an expert on the topic said at…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabbiosimilar substitutionsEnbreletanerceptHumiraINFLECTRA (infliximabdyyb)REMICADE (infliximab)Rituxanrituximab

Should Patients with Rheumatic Disease Switch from Biologic to Biosimilar?

Susan Bernstein  |  January 19, 2018

SAN DIEGO—Should patients with rheumatic diseases switch from a biologic to its biosimilar? At the 2017 ACR/ARHP Annual Meeting’s Great Debate, held Nov. 5, two rheumatologists argued whether to switch or stay put based on safety, efficacy and potential cost savings. First to the podium to make the case for switching, Jonathan Kay, MD, tweaked…

Filed under:Biologics/DMARDsDrug UpdatesInsuranceMeeting Reports Tagged with:ACR/ARHP Annual MeetingBiologicsBiosimilarsdrug costinsurance

Biosimilar SB2 May Work as Well as Infliximab for Rheumatoid Arthritis

Lara C. Pullen, PhD  |  January 8, 2018

In a 78-week study examining the interchangeability of infliximab with the biosimilar SB2, the treatments demonstrated long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis. Across all the study’s treatment groups, patients had similar treatment response rates, and the long-term clinical profile of SB2 was comparable with infliximab…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsimmunogenicityinfliximabRheumatoid Arthritis (RA)SB2

  • 1
  • 2
  • 3
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences